December 15, 2004 -- Amgen announced FDA approval of Kepivance (palifermin), the first and only therapy for severe oral mucositis. Oral mucositis is a side effect of high dose chemotherapy for hematologic cancer, currently considered an unmet medical need. We discuss the mechanism of the drug, the market for its current indication, and its larger potential...
